In Brief: Amgen Neupogen
Executive Summary
Amgen Neupogen: Granulocyte colony stimulating factor use in acute myeloid leukemia patients undergoing induction and consolidation chemotherapy unanimously recommended by FDA's Biological Response Modifiers Advisory Committee July 25. A 521-patient Phase III trial showed neutropenic episodes after induction therapy to be five days shorter compared to placebo and seven days less after consolidation treatment...